Comparison of the efficacy of drug-coated balloon angioplasty and conventional balloon angioplasty in the endovascular treatment of thrombosed arteriovenous dialysis fistulas.

angioplasty arteriovenous fistula dialysis drug‐coated balloon

Journal

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy

ISSN: 1744-9987

Titre abrégé: Ther Apher Dial

Pays: Australia

ID NLM: 101181252

Informations de publication

Date de publication:
21 Aug 2024

Historique:

revised: 15 07 2024

received: 02 05 2024

accepted: 09 08 2024

medline: 21 8 2024

pubmed: 21 8 2024

entrez: 21 8 2024

Statut: aheadofprint

Résumé

To evaluate the efficacy and safety of paclitaxel-coated balloon angioplasty in the treatment of thrombosed arteriovenous fistulas. This prospective, randomized, controlled study investigated the use of drug-eluting balloons in the treatment of the thrombosis of arteriovenous fistulas (AVFs) at our center between January 2018 and January 2023. A total of 246 patients were included in the study. The mean age of the patients was 61.3 ± 11.5 years. Of the patients, 150 (61%) were male and 96 (39%) were female. Angioplasty was performed using a plain balloon (PB) in 126 patients (51.2%) and a drug-coated balloon (DCB) in 120 (48.8%). The control images of the patients were obtained at the sixth and 12th months. Patency was evaluated during the follow-up. There was no significant difference between the two groups in terms of age, gender, hypertension, hyperlipidemia, diabetes, fistula location, or stenosis length. No significant difference was observed between the groups regarding the number of complications observed during and after the procedure. At the end of the sixth month, the patency rate was found to be 86.7% in the DCB group and 78.6% in the PB group. The 12th-month patency rate was 77.5% in the DCB group and 57.9% in the PB group. A significant difference was detected between the two groups in relation to the 6th- and 12th-month patency rates (p = 0.034 and p = 0.046, respectively). Drug-coated balloon angioplasty is an effective approach to the treatment of thrombosed AVFs, especially in terms of prolonging primary patency and reducing the need for secondary procedures.

Identifiants

DOI: 10.1111/1744-9987.14197 PMID: 39165149

pubmed: 39165149

doi: 10.1111/1744-9987.14197

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Kalantar‐Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021;398(10302):786–802.

Karkar A, Wilkie M. Peritoneal dialysis in the modern era. Perit Dial Int. 2023;43:301–314.

Choi SR, Park P, Han S, Kim C, Joo N, Kim JK, et al. Comparison of dynamic arterial and venous pressure between metal needles and plastic cannulas in incident hemodialysis patients with arteriovenous graft. J Vasc Access. 2021;22(1):42–47.

Thurlow JS, Joshi M, Yan G, Norris KC, Agodoa LY, Yuan CM, et al. Global epidemiology of end‐stage kidney disease and disparities in kidney replacement therapy. Am J Nephrol. 2021;52:98–107.

Özdemir M, Taydaş O, Danışan G, Ateş ÖF. Comparison of the complications and long‐term results of heparin‐coated and non‐heparin‐coated symmetric‐tip hemodialysis catheters. J Vasc Access. 2023.

Agarwal AK, Boubes KY, Haddad NF. Essentials of vascular access for home hemodialysis. Adv Chronic Kidney Dis. 2021;28(2):164–169.

Li Y, Shi Z, Zhao Y, Tan Z, Guo H, Lu Z. Comparative effectiveness and safety among different tip‐design hemodialysis long‐term catheters: a meta‐analysis. J Vasc Access. 2022;25:448–460.

Ibeas‐Lopez J. New technology: heparin and antimicrobial‐coated catheters. J Vasc Access. 2015;16(Suppl 9):S48–S53.

Tyagi R, Ahmed SS, Navuluri R, Ahmed O. Endovascular arteriovenous fistula creation: a review. Semin Intervent Radiol. 2021;38(5):518–522. https://doi.org/10.1055/s-0041-1736531

Stoecker JB, Li X, Clark TWI, Mantell MP, Trerotola SO, Vance AZ. Dialysis access‐associated steal syndrome and management. Cardiovasc Intervent Radiol. 2023;46(9):1168–1181.

Kim DH, Park JI, Lee JP, Kim YL, Kang SW, Yang CW, et al. The effects of vascular access types on the survival and quality of life and depression in the incident hemodialysis patients. Ren Fail. 2020;42:30–39.

Lučev J, Breznik S, Dinevski D, Ekart R, Rupreht M. Endovascular treatment of Haemodialysis arteriovenous fistula with drug‐coated balloon angioplasty: a single‐Centre study. Cardiovasc Intervent Radiol. 2018;41:882–889.

Yildiz I. The efficacy of paclitaxel drug‐eluting balloon angioplasty versus standard balloon angioplasty in stenosis of native hemodialysis arteriovenous fistulas: an analysis of clinical success, primary patency and risk factors for recurrent dysfunction. Cardiovasc Intervent Radiol. 2019;42:685–692.

Tan Z, Chan SXJM, Da Zhuang K, Urlings T, Leong S, Chua JME, et al. Recurrent stenoses in arteriovenous fistula (AVF) for dialysis access: cuttIng ballooN angioplaSTy combined wITh paclitaxel drUg‐coaTed balloon angioplasty, an observatIONal study (INSTITUTION study) [published correction appears in Cardiovasc Intervent Radiol. 2022 Feb 15]. Cardiovasc Intervent Radiol. 2022;45:646–653.

Lee HY, Kim CS, Han KD, Kim MJ. Comparison of the clinical outcomes between angiojet pharmacomechanical thrombectomy and hybrid surgical thrombectomy for thrombotic occlusion of hemodialysis access. Vasc Specialist Int. 2020;36(4):241–247.

Huang SM, Hsu H, Hii IH, Chang CH. Sedoanalgesia with intravenous midazolam and fentanyl for angioplasty of dysfunctional arteriovenous access: a retrospective single‐center analysis. J Vasc Access. 2023;24(4):715–721.

Abdul Salim S, Tran H, Thongprayoon C, Fülöp T, Cheungpasitporn W. Comparison of drug‐coated balloon angioplasty versus conventional angioplasty for arteriovenous fistula stenosis: systematic review and meta‐analysis. J Vasc Access. 2020;21:357–365.

Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, et al. Drug‐coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12‐month results from the IN.PACT SFA randomized trial. Circulation. 2015;13:495–502.

Huang C, Yao G, Hu R, Yang Y, Huang J, Ou F, et al. Outcome and risk factors of restenosis post percutaneous transluminal angioplasty at juxta‐anastomotic of wrist autogenous radial‐cephalic arteriovenous fistulas: a retrospective cohort study. Ann Vasc Surg. 2023;93:234–242.

Lundström UH, Welander G, Carrero JJ, Hedin U, Evans M. Surgical versus endovascular intervention for vascular access thrombosis: a nationwide observational cohort study. Nephrol Dial Transplant. 2022;37:1742–1750.

Wu V, Kalva SP, Cui J. Thrombectomy approach for access maintenance in the end stage renal disease population: a narrative review. Cardiovasc Diagn Ther. 2023;13:265–280.

Patanè D, Giuffrida S, Morale W, L'Anfusa G, Puliatti D, Bisceglie P, et al. Drug‐eluting balloon for the treatment of failing hemodialytic radiocephalic arteriovenous fistulas: our experience in the treatment of juxta‐anastomotic stenoses. J Vasc Access. 2014;15:338–343.

Speck U, Scheller B, Hamm B. Drug‐coated balloons for restenosis prophylaxis. Rofo. 2014;186:348–358.

Tzafriri AR, Muraj B, Garcia‐Polite F, Salazar‐Martín AG, Markham P, Zani B, et al. Balloon‐based drug coating delivery to the artery wall is dictated by coating micro‐morphology and angioplasty pressure gradients. Biomaterials. 2020;260:120337.

Katsanos K, Karnabatidis D, Kitrou P, Spiliopoulos S, Christeas N, Siablis D. Paclitaxel‐coated balloon angioplasty vs. plain balloon dilation for the treatment of failing dialysis access: 6‐month interim results from a prospective randomized controlled trial. J Endovasc Ther. 2012;19:263–272.

Kitrou PM, Katsanos K, Spiliopoulos S, Karnabatidis D, Siablis D. Drug‐eluting versus plain balloon angioplasty for the treatment of failing dialysis access: final results and cost‐effectiveness analysis from a prospective randomized controlled trial (NCT01174472). Eur J Radiol. 2015;84:418–423.

Mehrotra S, Paramasivam G, Mishra S. Paclitaxel‐coated balloon for femoropopliteal artery disease. Curr Cardiol Rep. 2017;19:10.

Björkman P, Peltola E, Albäck A, Venermo M. Peripheral vascular restenosis: a retrospective study on the use of drug‐eluting balloons in native arteries, vein grafts and dialysis accesses. Scand J Surg. 2017;106:158–164.

Yan Wee IJ, Yap HY, Hsien Ts'ung LT, Lee Qingwei S, Tan CS, Tang TY, et al. A systematic review and meta‐analysis of drug‐coated balloon versus conventional balloon angioplasty for dialysis access stenosis. J Vasc Surg. 2019;70:970–979.e3.

Çildağ MB, Köseoğlu ÖF, Akdam H, Yeniçerioğlu Y. The primary patency of drug‐eluting balloon versus conventional balloon angioplasty in hemodialysis patients with arteriovenous fistula stenoses. Jpn J Radiol. 2016;34:700–704.

Lookstein RA, Haruguchi H, Ouriel K, Weinberg I, Lei L, Cihlar S, et al. Drug‐coated balloons for dysfunctional dialysis arteriovenous fistulas. N Engl J Med. 2020;383:733–742.

Zhao Y, Wang P, Wang Y, Zhang L, Zhao Y, Li H, et al. Drug‐coated balloon angioplasty for dysfunctional arteriovenous hemodialysis fistulae: a randomized controlled trial. Clin J Am Soc Nephrol. 2023;18:336–344.

Swinnen JJ, Hitos K, Kairaitis L, Gruenewald S, Larcos G, Farlow D, et al. Multicentre, randomised, blinded, control trial of drug‐eluting balloon vs Sham in recurrent native dialysis fistula stenoses. J Vasc Access. 2019;20:260–269.

Liu C, Wolfers M, Awan BZ, Ali I, Lorenzana AM, Smith Q, et al. Drug‐coated balloon versus plain balloon angioplasty for hemodialysis dysfunction: a meta‐analysis of randomized controlled trials. J Am Heart Assoc. 2021;10:e022060.

Novak M, Matras P, Kavan J, Lambert L, Burgetova A. Angioplasty of dysfunctional dialysis fistula or graft with resveratrol‐excipient and paclitaxel‐coated balloon improves primary patency rates compared to plain angioplasty alone. J Clin Med. 2022;11:7405.

Björkman P, Weselius EM, Kokkonen T, Rauta V, Albäck A, Venermo M. Drug‐coated versus plain balloon angioplasty in arteriovenous fistulas: a randomized, controlled study with 1‐year follow‐up (the Drecorest ii‐study). Scand J Surg. 2019;108:61–66.

Roosen LJ, Karamermer Y, Vos JA, de Jong GM, Bos WJ, Elgersma OE. Paclitaxel‐coated balloons do not prevent recurrent stenosis in hemodialysis access fistulae: results of a randomized clinical trial. Italian J Vasc Endovasc Surg. 2017;24(2):35–40.

Yin S, Bhattacharya R, Cabral F. Human mutations that confer paclitaxel resistance. Mol Cancer Ther. 2010;9:327–335.

Liao MT, Lee CP, Lin TT, Jong CB, Chen TY, Lin L, et al. A randomized controlled trial of drug‐coated balloon angioplasty in venous anastomotic stenosis of dialysis arteriovenous grafts. J Vasc Surg. 2020;71:1994–2003.

Kim TI, Chen JF, Orion KC. Practice patterns of dual antiplatelet therapy after lower extremity endovascular interventions. Vasc Med. 2019;24:528–535.

Böhme T, Noory E, Beschorner U, Jacques B, Bürgelin K, Hirstein S, et al. Combined treatment of dysfunctional dialysis access with cutting balloon and paclitaxel‐coated balloon in real world. Vasa. 2023;52(4):284–289.

Littler P, Cullen N, Gould D, Bakran A, Powell S. AngioJet thrombectomy for occluded dialysis fistulae: outcome data. Cardiovasc Intervent Radiol. 2009;32(2):265–270.

Tang TY, Soon SXY, Yap CJQ, Chan SL, Tan RY, Pang SC, et al. Early (6 months) results of a pilot prospective study to investigate the efficacy and safety of sirolimus coated balloon angioplasty for dysfunctional arterio‐venous fistulas: MAgicTouch intervention leap for dialysis access (MATILDA) trial. PLoS One. 2020;15:e0241321.

Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel‐coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta‐analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e011245.

Schneider PA, Laird JR, Doros G, Gao Q, Ansel G, Brodmann M, et al. Mortality not correlated with paclitaxel exposure: an independent patient‐level meta‐analysis of a drug‐coated balloon [published correction appears in J Am Coll Cardiol. 2019 Feb 28]. J Am Coll Cardiol. 2019;73:2550–2563.

Söder HK, Manninen HI, Räsänen HT, Kaukanen E, Jaakkola P, Matsi PJ. Failure of prolonged dilation to improve long‐term patency of femoropopliteal artery angioplasty: results of a prospective trial. J Vasc Interv Radiol. 2002;13:361–369.

Lantis JC, Boone D. Standard versus prolonged inflation time in balloon angioplasty of atherosclerotic rat aortas. J Vasc Surg. 2011;54(3):925.